phase 1_completion
saveNational Cancer Institute US — tuvusertib (Phase I Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Adenocarcinoma, Endometrial Cancer, Ovarian Cancer
Data sources
globaldata
Found something off?
same company · ±60 days · 6
- phase 1 completionemavusertib hydrochloride: National Cancer Institute US — emavusertib hydrochloride (Phase I Trial Completion)Apr 30, 2026
- phase 1 2 initiationPEP-CMV: National Cancer Institute US — PEP-CMV (Phase I/II Trial Initiation)Apr 30, 2026
- phase 2 completionipilimumab: National Cancer Institute US — ipilimumab (Phase II Trial Completion)Apr 30, 2026
- phase 2 initiation(daratumumab + hyaluronidase (human recombinant)): National Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)Apr 29, 2026
- phase 1 completionundisclosed chemotherapy: National Cancer Institute US — undisclosed chemotherapy (Phase I Trial Completion)Apr 28, 2026
- phase 1 2 initiationsacituzumab govitecan: National Cancer Institute US — sacituzumab govitecan (Phase I/II Trial Initiation)Apr 27, 2026
comments(0)
5-min edit window · permanent after that